Andrew Cleeland is CEO of Fogarty Innovation, a non-profit medtech incubator based in Silicon Valley. He is a seasoned executive with over 30 years of leadership experience in the medical device industry across the private and public sectors.
Prior to joining Fogarty, Andrew led Medtronic’s Transcatheter Mitral Valve business following its 2015 acquisition of Twelve Inc., where he was CEO. Prior to Twelve, he was CEO of Ardian Inc. which was acquired by Medtronic in 2011. He currently serves on the boards of five companies: Saluda Medical, Zenflow Inc. (chairman), MMI Inc. (chairman), Francis Medical (chairman) and atHeart Medical. He also holds advisory positions at Longitude Capital, Arboretum Ventures and EQT Private Equity, and has been invited to serve on the UCSF-Stanford Pediatric Device Consortium, the board of MDIC, and Singapore’s Medtech Catapult.
